CSIMarket
 
Replimune Group Inc   (REPL)
Other Ticker:  
 
 
Price: $8.5300 $-0.31 -3.507%
Day's High: $9.01 Week Perf: -3.62 %
Day's Low: $ 8.48 30 Day Perf: 24.16 %
Volume (M): 3,204 52 Wk High: $ 24.81
Volume (M$): $ 27,329 52 Wk Avg: $15.19
Open: $8.75 52 Wk Low: $5.89



 Market Capitalization (Millions $) 568
 Shares Outstanding (Millions) 67
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -210
 Cash Flow (TTM) (Millions $) -109
 Capital Exp. (TTM) (Millions $) 4

Replimune Group Inc
Replimune Group Inc is a biotechnology company that specializes in the development of oncolytic immunotherapies to treat various forms of cancer. They have developed a platform called Immulytic that combines multiple engineering strategies to enhance the selective replication of viruses within tumors, ultimately leading to the destruction of cancer cells. The company aims to provide better treatment options for patients by harnessing the power of the immune system to fight cancer. Replimune Group Inc is based in Woburn, Massachusetts and was founded in 2015.


   Company Address: 500 Unicorn Park Drive Woburn 1801 MA
   Company Phone Number: 222-9600   Stock Exchange / Ticker: NASDAQ REPL
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Replimune Group Inc

Biotech Breakthroughs and Financial Surprises: Replimune Group Inc.'s Third Quarter Report Unveils Unexpected Results



Replimune Group Inc., a prominent player in the biotechnology sector, recently released its financial results for the fiscal third quarter of 2024. While the company showcased promising clinical trial outcomes, the financial report revealed some interesting findings. This article aims to outline the facts and analyze the implications of Replimune's financial performance.
Body:
1. Operating Deficit and Shareholder Expectations:
Replimune reported an operating deficit of $-56.54 million for the third quarter of 2024. As a smaller business in the biotechnology and pharmaceuticals sector, shareholders eagerly anticipate the company's forthcoming business model. Their focus appears to be less concerned with the current efficiency of Replimune within the industry.

Clinical Study

Replimune Demonstrates Encouraging Results in Cancer Trials Amidst Revenue Challenges.

Published Tue, Dec 5 2023 12:00 PM UTC



Replimune Group Inc., a leading biotechnology company focused on developing innovative oncolytic immunotherapies, recently announced its initial primary analysis results from the CERPASS clinical trial in advanced cutaneous squamous cell carcinoma (cSCC) and presented new data from the IGNYTE clinical trial of RP1 in anti-PD1 failed melanoma and non-melanoma skin c...

Replimune Group Inc

Revamp of Replimune Group Inc: Operating Deficit of $-63.831 Million Signals Challenges Ahead

During the past week, Replimune Group Inc stock experienced a decline of -0.28%. This brings the year-to-date performance of the stock to -46.11%. Despite this decline, the stock is still trading 8.5% above its 52-week low.
The decline in Replimune Group Inc stock could be attributed to the current state of the Biotechnology & Pharmaceuticals sector. Contributors in this sector are currently analyzing the second quarter of 2024 financial numbers. Unfortunately, Replimune Group Inc has reported an operating deficit of $-63.831 million for the July to September 30, 2023 reporting period. Additionally, the company has not cited any revenue during this time.

Shares

Replimune Group Inc Strengthens Leadership Team with Inducement Grant to New CFO

Published Tue, Sep 19 2023 8:01 PM UTC

Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WOBURN, Mass., Sept. 19, 2023 ? Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of oncolytic immunotherapies, today announced the grant of inducement equity awards to Emily Hill, the Company's newly appointed Chief Financ...

Replimune Group Inc

Replimune Group Inc Reports Significant Operating Loss of $55.648 Million in Q1 2024, Shaking the Biotechnology and Pharmaceuticals Industry

Investors Remain Cautious as Replimune Group Inc Reports Operating Loss in Q1 2024
The latest financial reports from Replimune Group Inc, a leading biotechnology and pharmaceutical company, have left investors concerned about its future performance. The company recorded an operating loss of $-55.648 million for the first quarter of 2024, and there have been no significant top-line achievements thus far.
During the April to June 30, 2023 reporting period, Replimune Group Inc experienced a widening deficit. The operating loss increased from $-42.253 million during the same period a year ago to $-49.555 million. As the company gears up for its next financial report due on November 02, 2023, experts are keenly observing the unfolding situation.






 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com